



VALUE ADDED MEDICINES **ONLINE SUMMIT**

Empowering the healthcare
community by improving
existing treatments

23-24-25 February 2021

Webinars report

Executive summary

- Innovating on existing molecules in the form of repurposing, reformulation and combination of therapies has the potential to deliver timely and effective solutions to unmet medical needs. However, the current European environment does not allow to fully exploit this approach.
- Value Added Medicines can empower patients by putting their needs at the center of therapy design, improving overall therapy outcomes.
- Three key enablers are needed in the EU to promote continuous and sustainable innovation: a fit-for-purpose regulatory framework ensuring predictability in early development, the recognition of innovation with proportionate incentives and the definition and the recognition of added value.

Improving treatments by rethinking, reinventing, and optimising existing medications




Figure 1 - VAM development strategies and use cases for VAMs during the Covid-19 pandemic.

Going beyond “What you see is all there is” to exploit the untapped potential of continuous innovation

It was estimated that using dexamethasone to treat Covid-19 patients led to

12000 Lives saved

Corresponding to

102000 Life years gained²

The Covid-19 pandemic has demonstrated that traditional pharmaceutical innovation, taking several years from the discovery of a drug target to the delivery of a novel therapy, does not move fast enough to address urgent unmet medical needs during a crisis. In this setting, **repurposing** has been key to the discovery of new therapeutic strategies.

In the RECOVERY¹ trial, **dexamethasone** was shown to be effective in combatting severe forms of Covid-19, demonstrating how off-patent molecules have enormous potential to deliver benefits to patients worldwide if enough resources are deployed for their evaluation.

While the potential of repurposing as a strategy for innovation has been demonstrated in the context of an acute crisis, the power of this approach extends far beyond emergencies. The importance of repurposing has been recognised in both the Pharmaceutical Strategy for Europe³ and Europe’s Beating Cancer Plan⁴, which were published by the European Commission in 2020 and 2021 respectively.

The initiatives promoted by the European Commission allocate resources and lay out a strategy to identify promising candidate molecules to be tested in new indications. Once a candidate is identified, pre-clinical and clinical testing are required to confirm its therapeutic potential. Collaboration among stakeholders is crucial to ensure that appropriate clinical evidence is generated to validate the most promising candidates.

¹ The RECOVERY Collaborative Group, “Dexamethasone in Hospitalized Patients with Covid-19”. N Engl J Med (2021); 384:693-704. <https://www.nejm.org/doi/full/10.1056/NEJMoa2021436>

² Águas, R., Mahdi, A., Shretta, R. et al., “Potential health and economic impacts of dexamethasone treatment for patients with COVID-19”. Nat Commun 12, 915 (2021). <https://doi.org/10.1038/s41467-021-21134-2>

³ Pharmaceutical strategy for Europe: <https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52020DC0761&from=EN>

⁴ Europe’s beating cancer plan: https://ec.europa.eu/health/sites/health/files/non_communicable_diseases/docs/eu_cancer-plan_en.pdf

While the clinical evaluation of a novel indication is an essential step in repurposing, it alone is not sufficient to maximise the societal benefit of this continuous innovation strategy. To fully benefit patients and healthcare systems, the new indication needs to be added to the label of the repurposed medicine (Fig 2). Unfortunately, the current regulatory framework often makes this process cumbersome, lengthy, and complex.

The [dexamethasone case](#) well exemplifies the regulatory inefficiencies that are associated with adding a new indication on the label of well-established molecules. Indeed, this drug is presently employed to save the lives of Covid-19 patients through off-label use in most European countries.

Unfortunately, repurposing is not the only continuous innovation strategy that is hindered by inadequacies and shortcomings of the EU regulatory framework. Manufacturers wanting to invest in the development of VAMs encounter significant hurdles (Fig 3). To fully exploit the untapped potential of innovation on off-patent molecules, change is needed at the European level.



Lack of official evaluation of the scientific evidence



Lack of data collection systems



Liability issues



Reimbursement issues



Supply issues



Patients' concerns

Figure 2 - Registering new indications of known molecules is instrumental in solving multiple issues that are associated with off-label prescribing⁵.

⁵ Pantziarka P. et al., "Repurposing drugs in oncology: From candidate selection to clinical adoption". Semin Cancer Biol (2021); 68:186-191. doi: [10.1016/j.semcancer.2020.01.008](https://doi.org/10.1016/j.semcancer.2020.01.008)




Figure 3 - VAM manufacturers experience significant hurdles at multiple stages of the medicine development path.

Engaging patients to create medicines that provide the improvements that are most relevant to them

Continuous innovation presents an opportunity to design treatments that truly have patients' needs at their core.

Better patient involvement leads to greater patient empowerment. On an individual level, this means that patients are significantly more likely to adhere to their therapy -and thus benefit from it- if they see the advantages of taking their medication and understand the consequences of non-adherence. On a broader level, listening to patient communities and integrating their experiences and needs into the development of new therapies enables manufacturers to design medicines that truly have unmet medical need and patient preferences at their heart.

Repurposing is not the only way in which VAMs use results in improved therapies. If appropriately promoted and fostered, continuous innovation can deliver benefits to a large and diverse range of patients.

Digital VAMs empower patients with respiratory diseases to take control of their therapy

Digital VAMs can be a valuable tool to enable patients to better understand their treatment and become confident in the management of their therapy.

The **combination** of known molecules with a digital component can support better therapy adherence through improved feedback and education of patients with respiratory diseases. For example, **smart inhalers** detect if a dose has been correctly administered and can track therapy adherence patterns, to inform better prescription choices by clinicians and identify patients that would need further training on inhaler use technique⁶.



Digital solutions have to be simple, so that patients can use them independently. The technology is there to make the patients' lives easier, not more complex.

*Monica Fletcher, OBE,
Honorary Research Fellow,
Usher Institute, University
of Edinburgh*

Reformulation delivers therapies that can keep at-risk patients out of harm's way

In healthcare systems worldwide, during the Covid-19 pandemic, reducing patient hospital visits became a key priority due to the risk of acquiring infections.

Through **reformulation**, VAMs allowed fragile non-Covid patients needing complex therapies to significantly reduce their visits to healthcare facilities. This is exemplified by the change in guidelines in the UK which led to a preference for administration of the VAM **Abraxane** -instead of the corresponding taxanes- to oncology patients, despite the price premium associated with the use of an improved formulation⁷. Thanks to its improved safety profile, this VAM reduced the need for longer hospital stays in a vulnerable category of patients.

⁶ Jansen E.M. et al., "Global burden of medication non-adherence in chronic obstructive pulmonary disease (COPD) and asthma: a narrative review of the clinical and economic case for smart inhalers". J Thorac Dis (2021). <https://jtd.amegroups.com/article/view/50478>

⁷ NHS England interim treatment options during the COVID-19 pandemic : <https://www.nice.org.uk/guidance/ng161/resources/interim-treatment-change-options-during-the-covid19-pandemic-endorsed-by-nhs-england-pdf-8715724381>

Enabling continuous innovation is most important in areas of unmet need

Continuous innovation has the potential to provide solutions in areas of unmet need where traditional approaches to innovation have failed. One such area is neurology, where many patients receive treatments that are generally considered suboptimal and cures are rare.

As the "[Value of Treatment for Brain Disorders](#)" report highlights, there is a need for cost-effective strategies that can provide timely improvements for patients. Thanks to their shorter development timelines and better affordability compared to originators, VAMs can provide important solutions for patients affected by brain disorders worldwide. Therefore, their value should be recognised, taking into account also the hidden costs for society that are associated with neurological conditions, such as the inability of patients to be employed.

Further examples of the benefits that VAMs can deliver to patients and healthcare systems, backed by extensive case studies and complemented by policy recommendations, are available on the Medicines for Europe website, in the IQVIA "[Case Studies for Value Added Medicines - Unlocking the potential of patient-centric continuous innovation](#)" report.

Defining the value of a medicine: what truly matters?

As demonstrated by the range of examples of how VAMs can improve the lives of patients, added value is at the heart of the definition of all categories of VAMs, prompting a discussion on how we define, quantify, and demonstrate the benefits of a therapy.



Companies would like to further invest into off-patent innovation. To enable this type of innovation we need a new ecosystem for VAMs. The Pharmaceutical Strategy for Europe is an opportunity to change the current ecosystem, recognising the value of this type of innovation and introducing a VAM-specific value framework. This element is essential for more predictability when deciding on future developments. Clear guidance and expectations need to be set out for the off-patent industry to enable continuous innovation for the benefit of patients, healthcare professionals and healthcare systems.

*Klara Marton, Vice-Chair of VAM sector group,
Medicines for Europe and Business Development
Director, Egis Pharmaceuticals PLC*

Identifying fair, structured, and predictable ways to determine the value of a given medicine is essential to drive continuous innovation on off-patent molecules.

Implementing a standardised framework for the quantification of added value in VAMs would enable significant predictability in terms of evidence generation requests and help to define what constitutes a proportionate and acceptable burden of evidence generation for manufacturers.

The VAM value evaluation framework proposed by the Syreon Research

Institute is designed to be used by payers and HTA bodies and can be adapted for implementation at the national level, to align with local views on what are the key parameters defining the value of a therapy. The framework features eleven value domains, distributed across five clusters (Fig 4).




Figure 4 - The VAM value evaluation framework proposed by the Syreon Research Institute consists of eleven value domains, divided into five clusters.

Delivering value to the healthcare community by creating a European ecosystem that fosters the development and uptake of VAMs

Currently, the US is leading the way in terms of VAM sales and the number of available VAMs on the market. This is primarily thanks to the establishment of a favourable regulatory environment that enables the streamlined development of VAMs within the dedicated [505\(b\)2](#) pathway.

The US market accounts for about **2/3** of global VAM sales⁷

⁷ IQVIA European Thought Leadership analysis, IQVIA MIDAS MAT Q2 2020

The US is the global leader in Value Added Medicines. Sales for top products in the US are about 10 times larger compared to the top products in Europe, so they drive global trends.

Aurelio Arias – Engagement Manager, European Thought Leadership, IQVIA



Dedicated regulatory procedures also enable smoother knock-on processes at later stages of VAM development, providing a clear pathway for companies to invest, for payers to assess the value of continued innovation and for

patients and healthcare professionals to gain access to improved treatment options. Overall, this results into a structured, predictable development path.

To unlock the benefits that can be delivered by VAMs, the EU should create an ecosystem that enables and fosters off-patent innovation.

VAMs should be recognised as a separate group of medicines in EU legislation, linking approval procedures, innovation frameworks and reimbursement processes to create an ecosystem that delivers better health to patients, solutions for healthcare systems and fair returns on R&D investments. In

February 2021, Medicines for Europe has released a [Whitepaper describing the key enablers needed for Creating a European ecosystem for safe, timely and affordable patient-centric innovation](#) (Fig 5).




Figure 5 - To build a EU environment that promotes and fosters continuous innovation, change is needed at multiple levels.

By recognising VAMs as a category of innovation with a dedicated pathway and tailoring the system of incentives provided by the EU pharmaceutical framework to support innovation throughout a molecule's lifecycle, we can achieve a comprehensive and resource-efficient EU pharmaceutical

industry, capable of delivering medicines that satisfy unmet medical needs and improve the lives of patients in Europe.



We recommend the establishment of a new and simplified regulatory pathway for VAMs, which would be defined under a new article 10.7 of the EU directive and form one of the three key pillars of the proposed EU environment for value added innovation (design a fit-for-purpose regulatory framework that will enable clarity early in the development, recognise VAMs as a category of innovation with appropriate incentives and recognise and define value for healthcare systems). This will give us the framework that we need to encourage VAMs development, providing VAMs the place they deserve in the healthcare ecosystem of tomorrow and in our society.

Arun Narayan – Chair of VAM sector group, Medicines for Europe

We would like to thank all the speakers and moderators who contributed to the 2021 Value Added Medicines online summit.

Webinar 1: Re-thinking continuous pharmaceutical innovation in the EU

- Aurelio Arias
- Gauthier Bouche
- Helen Lee
- Arun Narayan

Moderator: Annie Jullien Pannelay

The full recording of webinar 1 is available [here](#).

Webinar 2: What counts? Evaluation framework for added value of continuous innovation

- Zoltan Kalo
- Andras Inotai
- Tomas Tesar
- Frank Ulrich Fricke
- Donna Walsh
- Klara Marton

Moderator: Anke-Peggy Holtorf

Recorded presentations from webinar 2 are available [here](#) and [here](#).

Webinar 3: Improving care delivery and health outcomes with digital technologies

- Monica Fletcher, OBE
- Alessandro Monaco
- Job van Boven
- Mark Milton-Edwards

Moderator: Annie Jullien Pannelay

The full recording of webinar 3 is available [here](#).



All reasonable precautions have been taken to verify the information contained in this report. However, it should only be seen as a tool to explore the views of participants on the subject matter and it does not represent an official position of the Value Added Medicines Sector Group.